Haesner M, Buchali K, Pink V, Lips H
Nuklearmedizinische Klinik der Charité, Humboldt-Universität, Berlin, FRG.
Nuklearmedizin. 1992 Mar;31(2):48-52.
Since 1976 200 patients with multiple skeletal metastases from prostatic cancer were treated with 89Sr. In the present study the results were evaluated in order to confirm the efficacy of this therapy. Following the application of 3 injections each of 0 (n = 21), 37 (n = 65), 75 (n = 72), 100 (n = 25) or 150 (n = 17) MBq 89Sr subjective pain relief, scintigraphic follow-up observations, survival times and haematological complications were recorded. In comparison to the results of placebo administration the effects of 89Sr on pain were: in the placebo group deterioration 11%, no change 55%, improvement 17% and full pain relief 17% whereas in the Sr groups combined the corresponding figures were 3, 38, 26 and 33%. Pain relief correlated with the activity administered. A dose relationship to scintigraphic regression is probable, the latter correlating with pain relief. Due to a decrease of early deaths the survival rate increased during the first months after start of treatment but later on returned to the level observed in untreated patients. Pain relief and regressive scintigraphic findings were combined with increased marrow involvement which, however, did not by itself influence survival rates. 89Sr therapy is an effective additional treatment of patients with multiple skeletal metastases from prostatic cancer.
自1976年以来，200例前列腺癌多发性骨转移患者接受了89锶治疗。在本研究中，对结果进行了评估以证实该疗法的疗效。分别给予0（n = 21）、37（n = 65）、75（n = 72）、100（n = 25）或150（n = 17）MBq的89锶，各注射3次后，记录主观疼痛缓解情况、闪烁扫描随访观察结果、生存时间和血液学并发症。与给予安慰剂的结果相比，89锶对疼痛的影响为：安慰剂组病情恶化11%，无变化55%，改善17%，疼痛完全缓解17%；而在联合的89锶组中，相应数字分别为3%、38%、26%和33%。疼痛缓解与给予的活度相关。与闪烁扫描消退可能存在剂量关系，后者与疼痛缓解相关。由于早期死亡人数减少，治疗开始后的头几个月生存率有所提高，但随后又回到未治疗患者所观察到的水平。疼痛缓解和闪烁扫描的消退表现与骨髓受累增加相关，然而，骨髓受累本身并未影响生存率。89锶疗法是前列腺癌多发性骨转移患者一种有效的辅助治疗方法。
